Launch of preloaded IOL delivery system

Bausch + Lomb announced the U.S. launch of the EyeGility Inserter preloaded IOL delivery system. According to the company’s press release, this is specifically designed for preloaded enVista Aspire IOLs and Envy IOLs, and the company said that “the EyeGility inserter offers convenient one-handed operation and balanced push force for smooth delivery, with a silicone soft-tipped plunger that supports reliable IOL delivery with injection through a 2.4 mm incision.” The EyeGility Inserter is available in the U.S. as part of the enVista Aspire preloaded IOLs, with plans for enVista Envy lenses preloaded into EyeGility inserters to be available in the coming months.

Back to top

First U.S. patient randomized in pivotal study for intermediate to advanced dry AMD

i-Lumen Scientific announced the first U.S. patient has been randomized in the i-SIGHT2 pivotal study evaluating the i-Lumen AMD System in patients with intermediate to advanced dry age-related macular degeneration (AMD). According to the company’s press release, the i-SIGHT2 is a randomized, sham-controlled study designed to evaluate the safety and effectiveness of the i-Lumen AMD System, an investigational device that delivers a noninvasive, office-based bioelectric therapy intended to improve retinal electrophysiology and visual function in patients with vision loss due to intermediate to advanced dry AMD. “The therapy delivers low-level microcurrent stimulation through the eyelid to boost the transepithelial potential, repolarizing the retinal pigment epithelium (RPE) cells to improve photoreceptor cell function.”

Back to top

Two new offerings to boost success with presbyopia drop

Orasis Pharmaceuticals announced two new offerings to provide eyecare professionals more ways to help patients start and stay on Qlosi (pilocarpine hydrochloride ophthalmic solution)—the First Fill Free program, offered through pharmacy partner BlinkRx, and an in-office dispensing option. According to the company’s press release, First Fill Free provides patients with a no-cost first-fill on their eyecare professional’s prescription, with standard pricing thereafter. Qlosi is also now available for in-office dispensing in states where permitted.

Back to top

Company news

• IPG Photonics Corporation announced that it has entered into a binding offer to acquire Lumibird Medical. According to the company’s press release, “IPG believes that the combined medical businesses will create a scaled medical laser platform for growth with complementary established leadership in ophthalmology and urology.”

Back to top

ASCRS news and events

• ASCRS Live!: This educational dinner series is heading to several cities across the U.S. in 2026. Register for the next event, August 6, in Oklahoma City, Oklahoma.
• ASCRS Annual Meeting: Hotel rooms are now available for the 2027 ASCRS Annual Meeting. Book your 2027 hotel in San Diego early to get your preferred room and location.
• eyePAC: Support eyePAC, ASCRS’ political action committee (PAC), which helps protect cataract surgery and preserves surgeons’ ability to deliver high-quality care.*
• ASCRS Position Statement on Cyclodialysis with Scleral Reinforcement: ASCRS has released a new position statement addressing how physicians should report a controlled cyclodialysis with scleral reinforcement procedure using currently available CPT codes, until a dedicated Category III code takes effect on January 1, 2027. Read the full position statement.

Back to top

EyeWorld article of the week

The Summer issue of EyeWorld features articles on a number of digital advances in ophthalmology. In “Digital revolution hits visualization for cataract surgery,” several physicians discuss available digital visualization technologies, how they’re using them, and future directions. Read the article now.

Back to top

Research highlights

• A prospective multicenter randomized controlled trial at three eye centers in China sought to compare the postoperative rotational stability of three toric IOL platforms and identify platform-specific biometric factors associated with rotation. The study, published in the Journal of Cataract & Refractive Surgery, included 256 eyes of 172 cataract patients with regular corneal astigmatism that completed 3 months of follow-up after phacoemulsification with implantation of a TECNIS Toric II (Johnson & Johnson Vision), Clareon Toric (Alcon), or AT TORBI 709M (Zeiss). Participants in the trial were randomly assigned to 1 of the 3 toric IOL platforms. Results from the trial found that absolute rotation changed most prominently within the first week and then progressively stabilized. The authors concluded that “hydrophobic C-loop toric IOLs showed better early rotational stability than the hydrophilic plate-haptic toric IOL. Biometric correlates of rotation differed across platforms, supporting individualized toric IOL selection and postoperative monitoring.”
• Research published in Ophthalmology evaluated the access to diabetic retinopathy (DR) care by quantifying the geographic distribution of therapeutic and diagnostic procedures for DR across the U.S. This was a retrospective cohort study using the IRIS (Intelligent Research in Sight) Registry. Authors identified patients with ≥ 2 International Classification of Disease (ICD) codes for DR between January 1, 2013, and December 31, 2024. The study identified 11,254,015 therapeutic and 35,892,574 diagnostic procedures from 1,142,505 patients with DR. Study authors concluded that “DR-related diagnostic and therapeutic services were concentrated predominantly in urban practice locations, even after adjustment for population differences and disease burden, and support the need for strategies to improve access in non-urban communities.”

Back to top

Product news

• Orasis Pharmaceuticals and Aspen Australia announced that Aspen submitted a New Drug Application in Australia to the Therapeutic Goods Administration for the review and approval of BESKA (pilocarpine hydrochloride ophthalmic solution, 0.4%) for the treatment of presbyopia in adults (known as Qlosi in the U.S. market). Aspen will be responsible for the distribution and marketing of BESKA in Australia.
• Topcon Healthcare announced CE mark approval for GAIA, a fully automated ultra-widefield retinal imaging device offering a 209° field of view in a single capture.
• Iridex Corporation announced the expansion of its EyeProGPO product offering to include the company’s line of EndoProbe Handpieces.

*Contributions to eyePAC are entirely voluntary and are not tax deductible. Only ASCRS members who are citizens or legal residents of the United States may contribute. eyePAC must obtain, maintain and report the name, address, occupation, and employer of each contributor who gives more than $200 in a calendar year.

Back to top

---